Head-To-Head Review: Seer (NASDAQ:SEER) vs. Medpace (NASDAQ:MEDP)

Medpace (NASDAQ:MEDP) and Seer (NASDAQ:SEER) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, profitability, valuation and risk.

Insider and Institutional Ownership

78.0% of Medpace shares are owned by institutional investors. Comparatively, 75.2% of Seer shares are owned by institutional investors. 20.5% of Medpace shares are owned by insiders. Comparatively, 11.3% of Seer shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Medpace has a beta of 1.15, meaning that its stock price is 15% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.5, meaning that its stock price is 50% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Medpace and Seer, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medpace	0	9	3	0	2.25
Seer	1	0	0	2	3.00

Medpace currently has a consensus price target of $595.20, indicating a potential downside of 3.25%. Seer has a consensus price target of $4.00, indicating a potential upside of 108.33%. Given Seer’s stronger consensus rating and higher possible upside, analysts clearly believe Seer is more favorable than Medpace.

Earnings & Valuation

This table compares Medpace and Seer”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medpace	$2.53 billion	6.79	$451.12 million	$17.06	36.06
Seer	$13.75 million	7.73	-$73.60 million	($1.22)	-1.57

Medpace has higher revenue and earnings than Seer. Seer is trading at a lower price-to-earnings ratio than Medpace, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medpace and Seer’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medpace	17.67%	110.15%	24.84%
Seer	-478.05%	-27.23%	-23.99%

Summary

Medpace beats Seer on 10 of the 15 factors compared between the two stocks.

About Medpace

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance. The company was founded by August James Troendle in 1992 and is headquartered in Cincinnati, OH.

About Seer

Seer, Inc., a life sciences company, engages in developing and commercializing products to decode the biology of the proteome. It develops Proteograph Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation, and software to perform proteomic analysis to provide a solution that can be incorporated by nearly any lab for research use only. The company intends to sell its products for research use only, which cover academic institutions, life sciences, and research laboratories, as well as biopharmaceutical and biotechnology companies for non-diagnostic and non-clinical purposes. It operates in China, Australia, Eastern Europe, Israel, and Japan. The company was formerly known as Seer Biosciences, Inc. and changed its name to Seer, Inc. in July 2018. Seer, Inc. was incorporated in 2017 and is headquartered in Redwood City, California.